ReviewMaternal health, neonatology and perinatology2018
Association between furosemide in premature infants and sensorineural hearing loss and nephrocalcinosis: a systematic review.
Review in Maternal health, neonatology and perinatology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- From mechanisms to clinical practice: a review of diuretic therapy in pediatric nephrology.Pediatric nephrology (Berlin, Germany) · 2026Review
- Population Pharmacokinetics and Exposure-Safety Analysis of Furosemide in Preterm Infants.Journal of clinical pharmacology · 2026Article
- Incidence, risk factors, and outcomes of nephrocalcinosis in preterm infants: a prospective cohort study.Pediatric nephrology (Berlin, Germany) · 2025Observational
- Furosemide-Induced Nephrocalcinosis in Premature Neonates: A Critical Review of Observational Data.Children (Basel, Switzerland) · 2025Review
- Neutropenia Associated With Furosemide Administration in a Preterm Infant.Case reports in pediatrics · 2025Article
- The role of furosemide and fluid management for a hemodynamically significant patent ductus arteriosus in premature infants.Journal of perinatology : official journal of the California Perinatal Association · 2022Review
- Cumulative Doses Predict the Risk of Furosemide-Induced Electrolyte Abnormalities in Critically Ill Neonates.Therapeutics and clinical risk management · 2022Article
- Association between the Use of Diuretics and Size Reduction in Pediatric Atrial Septal Defect.Korean circulation journal · 2021Article
- Pharmacoepidemiology of Drug Exposure in Intubated and Non-Intubated Preterm Infants With Severe Bronchopulmonary Dysplasia.Frontiers in pharmacology · 2021Article
- The fetal inflammatory response syndrome: the origins of a concept, pathophysiology, diagnosis, and obstetrical implications.Seminars in fetal & neonatal medicine · 2020Article
- Furosemide use in Italian neonatal intensive care units: a national survey.Italian journal of pediatrics · 2020Article
- Pharmacoepidemiology of Furosemide in the Neonatal Intensive Care Unit.Neonatology · 2020Article
- Randomized comparison of continuous versus intermittent bolus furosemide in neonatal heart failure.Annals of pediatric cardiologyArticle
- Correction to: Association between furosemide in premature infants and sensorineural hearing loss and nephrocalcinosis: a systematic review.Maternal health, neonatology and perinatologyArticle
Corrections and comments
- Erratum issued
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Furosemide is a potent loop diuretic commonly and variably used by neonatologists to improve oxygenation and lung compliance in premature infants. There are several safety concerns with use of furosemide in premature infants, specifically the risk of sensorineural hearing loss (SNHL), and nephrocalcinosis/nephrolithiasis (NC/NL). We conducted a systematic review of all trials and observational studies examining the association between these outcomes with exposure to furosemide in premature infants. We searched MEDLINE, EMBASE, CINAHL, and clinicaltrials.gov. We included studies reporting either SNHL or NC/NL in premature infants (< 37 weeks completed gestational age) who received at least one dose of enteral or intravenous furosemide. Thirty-two studies met full inclusion criteria for the review, including 12 studies examining SNHL and 20 studies examining NC/NL. Only one randomized controlled trial was identified in this review. We found no evidence that furosemide exposure increases the risk of SNHL or NC/NL in premature infants, with varying quality of studies and found the strength of evidence for both outcomes to be low. The most common limitation in these studies was the lack of control for confounding factors. The evidence for the risk of SNHL and NC/NL in premature infants exposed to furosemide is low. Further randomized controlled trials of furosemide in premature infants are urgently needed to adequately assess the risk of SNHL and NC/NL, provide evidence for improved FDA labeling, and promote safer prescribing practices.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.